SPOTLIGHT -
Analysis suggests survival improved when cytoreductive nephrectomy added to immunotherapy in mRCC
The primary objective of the study was to assess the benefit of cytoreductive nephrectomy relative to immunotherapy regimens utilizing checkpoint inhibitors.
Latest olaparib data shared as next steps weighed for PARP inhibitors in prostate cancer
Olaparib has "ushered in the era of precision medicine in prostate cancer," said Maha Hussain, MD.
Smartphone app may help implement ERAS protocols for radical cystectomy
The app also provides patients with a socially distant alternative to in-person visits during the COVID-19 pandemic.
Sexual function continues after radical cystectomy
The majority of patients surveyed reported having at least some interest in sexual activity following surgery.
Enfortumab Vedotin shows robust survival outcomes in bladder cancer
The antibody-drug conjugate enfortumab vedotin significantly improved overall survival versus chemotherapy in a phase 3 trial.
Tivozanib May Be Superior Treatment for Patients With RCC, Study Finds
When compared with sorafenib, tivozanib showed improved progression-free survival, and a more manageable safety profile for patients with relapsed or refractory metastatic renal cell carcinoma.